London: Pharma major Pfizer on Wednesday reported that its COVID-19 vaccine is 95 per cent effective in phase 3 trials and would be applying for emergency US authorization within days.
The vaccine, developed with German partner BioNTech SE, has shown no major side effects. It demonstrated 95 per cent efficacy beginning 28 days after the first dose, Pfizer said.
“Additionally, the safety milestone required by the US FDA (Food and Drug Administration) for Emergency Use Authorization (EUA) has been achieved. To date, no serious safety concerns related to the vaccine candidate have been reported,” it said.
“Within days, we plan to submit a request to the US FDA for an EUA based on the totality of safety and efficacy data collected, as well as manufacturing data relating to the quality and consistency of the vaccine candidate,” it added.
The vaccine, however, will be required to be stored and transported at a temperature of minus 70 degrees, which is a huge challenge for countries like India.
NITI Aayog member (Health) and head of National Tast Force on COVID-19 Dr VK Paul has said that sufficient doses of the Pfizer vaccine, as required for the Indian population, will not be available.
Jajpur: Police have arrested a 60-year-old man for allegedly raping a minor girl in Odisha's…
New Delhi: A day before the first anniversary of Hamas’s October 7 attack, several rockets were…
Cuttack: Two persons allegedly slit the throat of an auto-rickshaw driver following a dispute over…
New Delhi: Ladakh activist Sonam Wangchuk and his supporters launched an indefinite hunger strike at Ladakh…
Sambalpur: The driver of a container truck was reportedly burnt alive as the vehicle caught…
Kolkata: West Bengal Chief Minister Mamata Banerjee has sought capital punishment for the accused in…
Bhubaneswar: Senior Congress leader Srikant Jen has urged Odisha government to convene a special session…
Berhampur: In a bid to revive and promote dying rural games, a sports competition was…